Jubilant Life Sciences Ltd - 530019 - Proposal To Issue Unsecured Bonds By Our Wholly-Owned Subsidiary Jubilant Pharma Limited (A Company Incorporated Under The Laws Of Singapore), Outside India, Under Regulation S Of The U.S. Securities Act Of 1933, As Amended.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that we have been informed that the Board of Directors of our material wholly-owned subsidiary, Jubilant Pharma Limited ('JPL') has, at its meeting held today i.e. February 25, 2019, approved the proposal to launch a offering of unsecured bonds (the 'Notes') outside India, under Regulation S of the U.S. Securities Act of 1933, as amended. The Notes are proposed to be (i) issued to institutional investors outside India and (ii) listed and quoted on the Official List of the Singapore Exchange Securities Trading Limited. The issuance of the Notes by JPL will not be a public offering in India. JPL proposes to undertake meetings with one or more potential international institutional investors located in different jurisdictions pursuant to the approval of its Board of Directors for the benchmark offering of the Notes as stated below: Date of Meetings Location of Meetings February 26, 2019 Singapore February 27, 2019 Hong Kong and London The schedule of meetings may undergo change due to exigencies on the part of the investors or JPL. A copy of the investor presentation to be shared with the investors during the meetings is attached herewith. Further, the investor presentation along with certain related additional information shall also be available on the website of the Company (www.jubl.com). Upon completion of these investors meetings and the book building process, JPL is expected to price the issuance of the Notes....25-02-2019